Tag Archives: epstein

Why the EPA’s recent pesticide battle could be a big deal

Why the EPA’s recent pesticide battle could be a big deal

By on 4 Mar 2016commentsShare

A battle between the U.S. government and a chemical giant revealed a fundamental flaw in the way we control pesticides — one that could be allowing thousands of unsafe chemicals to go undetected.

In a rare show of regulatory muscle, the Environmental Protection Agency (EPA) issued a Notice of Intent on Tuesday, announcing that it planned to cancel the sale of products that included a pesticide called flubendiamide as an active ingredient. The EPA has been monitoring these products, manufactured mainly by the company Bayer CropScience LP (and also by the smaller Japanese company Nichino America, Inc.), over the past few years. Studies have shown the pesticide was breaking down into a different, more deadly compound that was killing mussels and other invertebrates that fish rely on for food — a problem that the agency deemed serious enough to warrant the banning of all products of its kind.

The EPA’s move to ban the products is a novel one, and could signal a change in the way it regulates pesticides, particularly with issuing “conditional registrations,” a loophole that allows pesticides that have not undergone otherwise required safety testing to enter the market. Conditional registrations aren’t uncommon at all — according to a 2013 report released by the Natural Resources Defense Council, as much as 65 percent of more than 16,000 pesticides were first approved by the EPA for the market by way of conditional registrations.

Advertisement

David Epstein, a senior entomologist at the USDA’s Office of Pest Management Policy, says that these conditional registrations exist to aid growers of crops like vegetables, fruits, and nuts keep away pests. And in theory, they can be a beneficial aid to help smaller growers — but the process isn’t perfect.

“It’s a risk-benefit analysis,” Epstein told Grist, explaining that registrants are evaluated for risk in terms of things like human health, environmental safety, and non-target effects, and then they weigh the pesticide’s potential benefits to farmers. Epstein said that flubendiamide, a pesticide he’s used himself on crops, is an important tool for farmers to keep away harmful pests. The conditional registration process, he said, is a way to help growers get pesticides like these more quickly.

“It’s an evolving process,” he said. “Mistakes are made and corrected, and then we and move on.”

But there’s a big problem, according to Nathan Donley, a staff scientist at the Center for Biological Diversity and an expert on pesticide regulations.

“The EPA has no way of tracking these conditional registrations,” he told Grist. “During the normal regulatory process, the public can review docs and comment. But in conditional registration, it all happens backdoor; the public doesn’t get to see.”

Donley argues that the fundamental concept of conditional registration is flawed, and should be shut down until the EPA can better regulate pesticides.

“There’s more than enough pesticides on the market,” said Donley. “If a chemical company can’t demonstrate that its pesticide is safe, then that pesticide shouldn’t be on the market.”

The latest flubendiamide news is only the most recent skirmish in a battle that’s been brewing for months between Bayer, a German chemical giant worth $42 billion that produces the pesticide under the trade name Belt, and the EPA. It all began back in 2008,  when the EPA issued a conditional registration for flubendiamide — the chemical was legal to manufacture, but only under the condition that the companies must produce toxicity data on the impact of its use over the next few years, to fill in gaps in the original risk assessment. The EPA gave Bayer a generous five years to conduct scientific studies to prove that flubendiamide is safe for aquatic invertebrates, or the pesticide would have to go. Bayer agreed that it would voluntarily cancel the products if these stipulations weren’t met.

Seven years later — two years longer than expected — studies conducted by the EPA found that flubendiamide was having adverse effects on aquatic invertebrates. In January, the EPA gave Bayer the sign: a notice that, as they had agreed, Bayer must withdraw its flubendiamide pesticides. But last month, Bayer flat-out refused. In a statement, the company said that it “instead will seek a review of the product’s registration in an administrative law hearing,” asserting that the product was safe. It was a bold move, one that triggered outrage among environmentalists, many of whom demanded that Bayer play by the rules.

Now, it’s a stalemate, with EPA demanding flubendiamide products be banned, and Bayer resisting. But the damage, unfortunately, is already done. In California alone, 42,495 pounds of flubendiamide were sprayed onto 521,140 acres in 2013. In some places, it was applied six times in one year, misted over crops like soybeans, alfalfa, watermelon, almonds, peppers, and tobacco. In many cases, the EPA asserts, it was also being sprayed over wildlife.

The EPA’s notice to Bayer is out in the open, but flubendiamide isn’t leaving yet. According to NPR, Bayer is demanding a hearing before an administrative law judge before it makes any moves. The case has provoked renewed questions about what role the EPA should — and shouldn’t — play in pesticide regulations, and how to prevent unsafe chemicals from being unleashed on the planet.

Share

Please

enable JavaScript

to view the comments.

Find this article interesting?

Donate now to support our work.Climate on the Mind

A Grist Special Series

Get Grist in your inbox

See original article here:  

Why the EPA’s recent pesticide battle could be a big deal

Posted in alo, Anchor, FF, G & F, GE, LAI, ONA, Radius, Uncategorized | Tagged , , , , , , , , , , , | Comments Off on Why the EPA’s recent pesticide battle could be a big deal

The Harvard Medical School Guide to a Good Night’s Sleep – Lawrence Epstein & Steven Mardon

READ GREEN WITH E-BOOKS

The Harvard Medical School Guide to a Good Night’s Sleep
Lawrence Epstein & Steven Mardon

Genre: Health & Fitness

Price: $1.99

Publish Date: October 16, 2006

Publisher: McGraw-Hill Education

Seller: The McGraw-Hill Companies, Inc.


Put your sleep problems to rest with this proven six-step plan How many times have you heard it's important to get a good night's sleep? It sounds simple, but it isn't always easy. Now one of the nation's leading sleep experts gives you a step-by-step program for overcoming sleep problems from insomnia and snoring to restless legs syndrome and sleep apnea. Dr. Lawrence Epstein of Harvard Medical School reveals his proven six-step plan to maximize your nights and energize your days. He explains the health benefits of sleep and identifies signs of sleep problems as he gives in-depth advice on how to: Turn your bedroom into the optimal sleep environmentFinally overcome insomniaSilence buzz-saw snoringRelax restless legsDeal with daytime exhaustionDetermine if sleep medication is right for youImprove your sleep by improving your child's sleep

Link – 

The Harvard Medical School Guide to a Good Night’s Sleep – Lawrence Epstein & Steven Mardon

Posted in FF, GE, LAI, oven, Uncategorized | Tagged , , , , , , , , | Comments Off on The Harvard Medical School Guide to a Good Night’s Sleep – Lawrence Epstein & Steven Mardon

The Science Behind the World’s Greatest Athletes

Mother Jones

<!DOCTYPE html PUBLIC “-//W3C//DTD HTML 4.0 Transitional//EN” “http://www.w3.org/TR/REC-html40/loose.dtd”>

At the 1964 Winter Olympics, Eero Mäntyranta won the 15 kilometer cross-country skiing competition by a whopping 40 seconds—a margin of victory that has never been equaled. That same year, he won the 30 kilometer race by a full minute. So what made this legendary Finnish skier such a success?

According to sports journalist David Epstein, Mäntyranta became the “greatest endurance athlete” of his generation in part because of a single mutation to his erythropoietin receptor (EPOR) gene, which helps regulate the production of red blood cells. Remember Lance Armstrong’s blood doping scandal? It turns out that because of his DNA, Mäntyranta had a similar advantage over his competition—but without ingesting or injecting a single cell. Mäntyranta “produced about 50 percent more oxygen-carrying red blood cells than a normal person,” explains Epstein on this week’s episode of the Inquiring Minds podcast. “So he essentially was naturally what…Lance Armstrong was through doping technology.”

Epstein says Mäntyranta’s EPOR mutation is the clearest example of a “sports gene”—a single genetic variant that has the ability to turn someone into a superior athlete. But these genes are rare. More often, says Epstein (whose recent book is also called The Sports Gene), “we’re talking about networks of genes and suites of traits that make people better suited to some sports than others.”

Saying that some people are “better suited” than others sounds a lot like the idea that some of us are born more talented. But in recent years, much of the sports community has embraced the notion that achievement in athletics is attributable largely to logging 10,000 hours (or so) of dedicated training. The “10,000 hour” rule also permeates education in other domains, such as music and chess, where complex skills need to be developed. But with athletes like Mäntyranta in the competition, can this status quo idea possibly still hold true? And what, exactly, is the scientific recipe for building an elite athlete?

Here are a few of the key factors that Epstein lays out:

Start with the right genes. Mäntyranta’s EPOR mutation isn’t the only gene variant that can make or break an athletic career. On chromosome two of the human genome, there is a gene that codes for a protein called myostatin. (Myo meaning “muscle,” and statin meaning “to halt.”) For most people, this gene does exactly what its name suggests—it stops the production of muscles. But in rare cases, says Epstein, “someone has a mutant version, and it basically doesn’t tell their muscles to stop growing on time, and they end up being really, really muscle-bound.”

Perhaps not surprisingly, explains Epstein, the first adult determined to have this mutation was a professional sprinter. But it’s been detected in young children, as well. In 1999, for instance, a bouncing baby boy with seemingly superhuman strength was born in Germany. Unlike his roly-poly peers, this baby was ripped. The muscle mass in his lower limbs was off one end of the charts, while his limited body fat was off the other end.

When this “Superbaby” was tested for the presence of myostatin, none was detected in his blood. And other babies with similar mutations have begun to pop up, including Liam Hoekstra, who apparently could do a difficult gymnast move called the iron cross by the time he was 5 months old and could do a pull-up at eight months.

But if one gene can have such a significant effect, what other gene variants might be combined in a person to optimize athletic performance?

In his book, Epstein cites Alun G. Williams and Jonathan P. Folland, scientists in England who are studying 23 gene variants strongly linked to athletic endurance. The chance that any single individual currently on the planet has all 23 variants is incredibly small—less than one in a quadrillion (one thousand million million). The most any one of us can hope for is about 16 of these 23. The chance of having none of these variants, or very few of them, is also extremely small. Most of us have some but not too many. The end result? We need to train to build up endurance.

But genetics can also make a big difference when it comes to that training. “No two people respond to the medicine of training the same way because of differences in their genes,” says Epstein. “And so it’s turning out that the talent of trainability—the ability to get more biological adaptation out of your one hour of training than the next guy or the next girl—is really the most important kind of talent.”

But if we can’t change our genes, what can we do to become better athletes?

Learn to to predict the future. When it comes to professional baseball, says Epstein, “keep your eye on the ball” is useless advice. That’s because Major League pitches take far less than half a second to reach the plate—they’re simply moving faster than the eye can track. What batters are actually keeping track of is a specific pattern of movements that the pitcher is making.

Ted Williams in 1957, on his way to the Major League batting title. AP

The ability to predict where the ball will go based on how the pitcher releases it is the real talent of an all-star hitter. That’s why Mariano Rivera could strike out batter after batter with one pitch: a 90+ mile-per-hour cut fastball whose final destination was very difficult to predict. With just a subtle difference in how much pressure he put on the ball with two of his fingers, he could alter its course dramatically.

That’s also why no amount of trips to the batting cage will turn you into a slugger like Albert Pujols or Ted Williams. “We’ve only just realized that pitching machines are totally worthless for baseball practice,” explains Epstein, “because they don’t teach you to read body movements the way that you need to.”

Putting this idea to the test, softball pitcher Jennie Finch struck out Pujols and other Major League batters during the 2004 Pepsi All-Star Softball Game—her windup and delivery confounded their ability to predict where the pitch will go, despite the fact that she threw a bigger ball.

To understand how complex skills like hitting a small projectile traveling at speeds of over 90 miles per hour are performed, consider a famous study in which chess players of different levels were given a few seconds to study a chess board. What separated the experts from the amateurs was the fact that grand masters could memorize the location of pieces on the board after looking at it for just three seconds. At first, it seemed as though they had superhuman memory skills. But when the scientists asked them to memorize the placement of pieces on a board that didn’t conform to the rules of the game, they were no better than novices. In other words, what grand masters have actually developed is the ability to organize the board into meaningful units in their mind’s eye—what psychologists call “chunks”—that they can then easily recall.

Major League Baseball players can’t hit Jennie Finch’s pitches. C5813/Wikimedia Commons

We all use chunking to remember complex things: “If I gave you 20 random words right now, you’d have a lot of trouble repeating them back to me,” explains Epstein. “But, if I gave you a 20-word meaningful sentence, you might be able to repeat it back to me or very closely.” Why? Because “you’ve learned a system of grammar and groups of words and phrases that you can break down into meaningful chunks. So, you don’t have to…rely on your working memory.” And, adds Epstein, “it turns out sports works in a very similar way.”

So it’s not that MLB players have superhuman reflexes; instead, over the course of many years of training, they learn to “read” a pitcher’s upper body movements and predict where the ball will end up. “It’s really this kind of cognitive expertise that they’ve learned that allows them to look as if they’re reacting faster than is humanly possible,” says Epstein. “They are judging the field—their version of the chess board—and seeing what’s going to come in the future.”

Sample many sports in childhood—don’t specialize too early. As every parent knows, elite athleticism comes at a high price in the US, with many coaches pressuring talented children to start specialized practice immediately—often to the exclusion of other sports and activities. “AAU basketball has a second graders’ national championships now,” notes Epstein. “This is like kids who are over-hand heaving a ball at a 10-foot rim. They’ve convinced parents it’s like an important part of the scouting pipeline and their kids will get behind if they don’t go.”

Epstein argues that this push towards specialization—which he attributes to the popularization of the 10,000 hours rule—has been a “disaster.”

“There’s now a pretty strong body of evidence that we’ve over-specialized kids too early, and it actually makes them worse athletes,” he says. What Epstein is getting at is that there seems to be a critical “sampling period” before puberty, during which many eventual professional athletes play a variety of sports. Hyper-specialization makes it harder for kids to find the sport that is best suited to their biology. As an example for parents to follow, Epstein points to two-time NBA most valuable player Steve Nash, who didn’t start playing basketball until he was 12 or 13.

Grow up in a small town. The trend towards hyper-specialization might even explain why professional athletes come disproportionately from small towns, far away from elite training programs, instead of from major metropolises. If you’re from a city with a population of more than 5 million people, you’re actually less likely than the average Joe to make it to the NBA. If you come from a town of 50,000 to 99,000 people, your chances are 11 times greater than average of making it to the NFL or the NBA. These towns “are vastly over-represented for producing elite athletes,” says Epstein, “because they’re big enough to have a team, and small enough to avoid all of the hyper-specialization that the 10,000 hours has caused.”

Take a scientist’s approach to your own training. Ultimately, as scientists learn more about the biology of athletic prowess and the skills we need to excel at specific activities, what’s becoming clear is that training needs to be more individualized. Given the highly variable nature of our genes, what can you do to make sure that you’re using those training hours most effectively? Think like a scientist: test and retest your assumptions constantly.

“In studies of kids who go on to become elite, whether it’s in chess, sports or music,” says Epstein, “they tend to more often exhibit that self-regulatory behavior where they’re almost taking a scientist’s view of themselves…and continually evaluating and evaluating. And they better figure out what works for them.”

This episode of Inquiring Minds, a podcast hosted by neuroscientist and musician Indre Viskontas and best-selling author Chris Mooney, also features a discussion with skeptical pediatrician Clay Jones.

To catch future shows right when they are released, subscribe to Inquiring Minds via iTunes or RSS. We are also available on Stitcher and on Swell. You can follow the show on Twitter at @inquiringshow and like us on Facebook. Inquiring Minds was also recently singled out as one of the “Best of 2013” on iTunes—you can learn more here.

See original:  

The Science Behind the World’s Greatest Athletes

Posted in Anchor, FF, GE, LAI, LG, ONA, Radius, Uncategorized, Venta, Vintage | Tagged , , , , , , , | Comments Off on The Science Behind the World’s Greatest Athletes

Darrell Issa Investigation Benefits Ex-Aide

Mother Jones

<!DOCTYPE html PUBLIC “-//W3C//DTD HTML 4.0 Transitional//EN” “http://www.w3.org/TR/REC-html40/loose.dtd”>

Sen. Jay Rockefeller (D-W. Va.) has accused House oversight committee chairman Darrell Issa (R-Calif.) of inappropriately intervening in an ongoing Federal Trade Commission case against a company being represented by a legal group run by a former Issa staffer. Last month, Issa sent a letter to the FTC questioning testimony the agency had gathered for the case, which targets a medical testing company called LabMD. The firm allegedly exposed the personal data of almost 10,000 people. On Thursday morning, Issa’s committee held a hearing that featured LabMD CEO Michael Daugherty and focused on whether the FTC has overstepped its bounds by investigating companies that experience data breaches.

“You are using heavy-handed, bullying tactics to undermine due process and to inappropriately assist the defendant LabMD,” Rockefeller wrote in a recent letter to Issa, which was obtained by Mother Jones. “The inappropriate timing and nature of your investigation are buttressed by the revelation that LabMD is being represented by a former member of your committee staff.” Rockefeller was referring to Daniel Epstein, who from January 2009 to August 2011 served as an oversight committee counsel. Epstein now heads a nonprofit legal advocacy group called Cause of Action, which is representing LabMD in the FTC matter.

Continue Reading »

See original: 

Darrell Issa Investigation Benefits Ex-Aide

Posted in Anchor, Cyber, FF, GE, LAI, LG, ONA, PUR, Radius, Uncategorized, Venta, Vintage | Tagged , , , , , , , , , | Comments Off on Darrell Issa Investigation Benefits Ex-Aide